Pioneering Innovation Together: Insights from the BioPharm Networking Event in Berlin

EventsClinical TrialsBiotech Industry TrendsGlobal CollaborationInnovation in Life Sciences
Written By Haley Lassiter

The recent BioPharm Networking Panel Discussion in Berlin proved to be an unforgettable gathering of minds, driven by the spirit of innovation and global collaboration. Co-hosted by Pathways Preclinical Partners, Oximio, and PVR (People. Value. Research), the event brought together leading experts, decision-makers, and innovators from across the life sciences industry to explore the future of biotech.

With Berlin as the backdrop—a hub to over 300 biotech companies and more than 8,000 life science professionals—this event highlighted why the city is emerging as a powerhouse of biomedical advancement. The panel focused on critical topics shaping the future of the biopharmaceutical industry, from AI-driven transformation in clinical trial design to real-world infrastructure limitations like hospital WiFi and data transfer challenges.

Our CEO, Jae Sly, PhD, MBA, delivered opening remarks, setting the tone for a day of bold ideas and strategic insight. She was joined by a distinguished panel of leaders:

  • Zayheda Khan, Chief Commercial Officer and UK Managing Director, Oximio

  • Dr. Dan Goldstaub, Scientific Co-Founder, Phase V

  • Christoph Schäfer, CEO, CIS Biopharma

  • Marion Hitchcock, PhD, Managing Director, Gene & Cell Therapies Incubator Berlin, Bayer

  • Oleh Makarchuk, CEO, PVR

Key Takeaways:

  • Artificial Intelligence and Machine Learning are revolutionizing how trials are conceptualized, conducted, and optimized—raising both opportunity and regulatory questions.

  • Global clinical trial acceleration requires not only novel technology but also strong partnerships with CROs and specialized service providers who can bridge operational gaps.

  • Tailored solutions and regulatory alignment are essential in moving therapies from bench to bedside faster and more efficiently.

The audience played an integral role, asking thought-provoking questions that pushed the dialogue forward. The lively exchange of ideas underscored our shared commitment to smarter, more responsive pathways in drug development.

To conclude the day, attendees were treated to a breathtaking concert by Musica Impact, conducted by Samuel Gal A., at the Berlin Philharmonie—a fitting celebration of art, science, and human connection.

We’re proud that this event sparked not just conversations, but momentum. Given its overwhelming success, the BioPharm Networking Panel is set to become an annual tradition, continuing to bring together leaders who are shaping the future of biotech through purpose-driven collaboration.

Thank you to all the speakers, partners, and attendees who made this event possible. Together, we’re not just imagining a better future for biopharma—we’re building it.

Stay tuned for more in 2026. 🌍💡

Haley Lassiter